Exploring the potential of Ayush-64 in mitigation of post-coronavirus disease of 2019 complications of Delta variant of severe acute respiratory syndrome coronavirus 2.

BACKGROUND: SARS-CoV-2 continues to exert a profound impact on global health by inducing inflammatory and metabolic dysregulation. PURPOSE: Our study investigates the therapeutic potential of polyherbal formulation, Ayush-64, in mitigating SARS-CoV-2 Spike-induced immunometabolic modulations. The COVID-19 illness has long-lasting effects in terms of multi-organ effects, particularly in the nervous system. STUDY DESIGN: With post-COVID complications, we assess the efficiency of this phytocompound at transcript and protein levels by utilizing in vitro transfection models with wildtype and Delta mutants of Spike protein in lung (A549) and neural (IMR-32+LN-229) co-culture systems. METHODS: To identify specific metabolic and structural modulations, we also made assessments through LC-MS and Raman spectroscopy. RESULTS: Our findings demonstrate that Ayush-64 restores ATP production, enhances fatty acid oxidation, and restores cofactors' levels such as biotin and pyridoxal phosphate (PLP), all of which are hijacked upon viral infections. Notably, the Delta variant induces greater inflammation, yet Ayush-64 effectively restores such immunomodulations. Key phytochemicals, such as betulin, sweroside, picroside, and amarogentin, contribute to the stabilization of lipid membranes and the reduction in inflammatory signaling with Ayush-64 exhibiting targeted metabolic recovery in both lung and neural microenvironments. CONCLUSION: Therefore, our results underscore Ayush-64's role in re-establishing immunometabolic balance and enhancing neural resilience, highlighting utilization of formulation against SARS-CoV-2 viral infection.